2023-12-07 04:30:00
EXCLUSIVE MAINTENANCE – The boss of the French laboratory is striving to convince investors of the relevance of his strategic shift and his priority given to research.
Six weeks after weathering a severe stock market storm, Paul Hudson, the CEO of Sanofi, is back on deck this Thursday in New York to convince investors. On October 27, this French flagship of the CAC40 plunged 19% on the stock market, sending 25 billion euros of capitalization soaring. The violent sanction of the group’s abandonment of its objective of reaching a margin of 32% in 2025, justified by an increase in investments in R&D.
The announcement of the split of its consumer health division, which brings together its non-prescription medications including the famous Doliprane, was not enough to calm investors’ headaches. Worse, the “new chapter” of the strategy that the British leader promised to write remained inaudible. Since then, the stock has barely recovered, proof of the markets’ distrust of Sanofi.
“We need to attract new investors”
“The investors I have met since October 27 gave us an A for the strategy presented that day, but a C+ for…
This article is reserved for subscribers. You have 89% left to discover.
Do you want to read more?
Unlock all items immediately.
Already subscribed? Log in
#time #Sanofi #global #leader #pharmacy